- |||||||||| Preclinical, Journal: Novel non-HAP class A HBV capsid assembly modulators have distinct in vitro and in vivo profiles. (Pubmed Central) - Dec 25, 2023
These so-called non-HAP CAM-As have intriguing properties in cell culture but also clear virus-infected cells from the mouse liver in a gradual and sustained way. We believe they represent a considerable improvement over previously reported molecules and may one day be part of curative treatment combinations for chronic hepatitis B.
- |||||||||| RG7907 / Roche, ALG-005398 / Aligos Therap
NON-HAP CLASS I CAPSID ASSEMBLY MODULATORS HAVE DISTINCT PROFILES AND A DIFFERENTIATED MECHANISM OF ACTION () - Oct 23, 2022 - Abstract #AASLD2022AASLD_704; Their underlying mechanisms of action governing in vivo HBsAg reduction are also clearly differentiated. Since optimized non-HAP CAM1s have suitable ADME / tox profiles, they represent an attractive class of molecules for further development as a part of potential functional cure regimens for CHB, offering a potential advantage over HAPs.
|